A press release was issued by Satsuma Pharmaceuticals, Inc. regarding the update of the development plan and fundraising for the intranasal migraine medication STS101.
- Business
Announcement Date: March 1, 2021 (U.S. Time)
"First Report"
detail: Here please refer to the original press release.
(overview)
Satsuma Pharmaceuticals, Inc. announced that it has updated the development plan for its intranasal migraine medication, STS101, which is currently under development.
The latest STS101 development plan includes a new Phase 3 efficacy trial (EMERGE) expected to start in mid-2021, with major results anticipated in the second half of 2022.
The private placement fundraising announced in the second press release has secured sufficient funds to operate the company until the second half of 2023.
"Second Report"
detail: Here please refer to the original press release.
(overview)
Satsuma Pharmaceuticals, Inc. announced that it successfully raised approximately 80 million U.S. dollars through a private placement.
Our company, which is a co-founder of the company, is also participating in the fundraising, and the closing is expected on March 3, 2021.
This fundraising enables the continuation of the clinical development of STS101, as announced in the first press release.